| Target Molecule | c(RGDyK) |
| Synonyms | Cyclo(-RGDyK); Cyclo(Arg-Gly-Asp-D-Tyr-Lys); cyclo(-Arg-Gly-Asp-D-Tyr-Lys); cyclic RGD peptide; αvβ3 integrin ligand |
| CAS Number | 217099-14-4 (also reported as 250612-42-1) |
| Sequence | Cyclo(-Arg-Gly-Asp-D-Tyr-Lys-) (head-to-tail cyclic pentapeptide) |
| One-Letter | cyclo(-RGDyK) (y = D-Tyr) |
| Cyclization | Head-to-tail backbone amide (homodetic cyclic pentapeptide; no disulfide) |
| Labeling Handles | Tyrosine phenol (direct radioiodination) and lysine ε-amine (dyes, chelators, carriers) |
| Molecular Formula | C₂₇H₄₁N₉O₈ |
| Molecular Weight | 619.7 |
| Service Category | Custom Synthesis / Pharmaceutical Peptide R&D |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98%, ≥99% by HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Trifluoroacetate (TFA) or Custom Acetate Options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with Head-to-Tail Cyclization |
| Modification Options | Direct radioiodination, fluorescent dye conjugation, chelator attachment |
| Water Content | Per specification (Karl Fischer) |
| Solubility | Soluble in water and DMSO |
| Available Scale | Milligram (R&D) to Kilogram (Commercial Manufacturing) |
| Analytical Data | Comprehensive COA, HPLC, MS identity; amino-acid analysis on request |
| Usage | Raw material synthesized strictly for laboratory research, pharmaceutical R&D, and industrial manufacturing. Not a finished drug. |
c(RGDyK) (CAS 217099-14-4) is a head-to-tail cyclic pentapeptide containing the Arg-Gly-Asp motif and a D-tyrosine residue. We synthesize this specific structure as a high-purity raw material for integrin αvβ3-targeted research and pharmaceutical development.
We utilize optimized solid-phase peptide synthesis (SPPS) followed by precise head-to-tail backbone amide cyclization. This platform ensures highly efficient amino acid coupling and strict control over deletion impurities, yielding batches that meet rigorous HPLC purity specifications.
Yes. The standard structure provides independent D-tyrosine and lysine handles. Our modification services can utilize the tyrosine phenol for direct radioiodination and the lysine ε-amine for conjugation with fluorescent dyes (like Cy5.5), chelators, or targeted carriers.
Our infrastructure transitions seamlessly from milligram-scale laboratory batches to kilogram-scale commercial production. We maintain rigorous batch-to-batch consistency essential for industrial-scale pharmaceutical formulation.
We serve as a strategic technical partner. Our team assists with sequence stability testing, impurity profiling, and the provision of complete analytical documentation to accelerate downstream targeted drug delivery and imaging probe projects.
c(RGDyK), defined by the head-to-tail cyclic sequence cyclo(-Arg-Gly-Asp-D-Tyr-Lys-), is a widely utilized scaffold for building αvβ3 integrin-targeted imaging agents. Synpeptide provides comprehensive synthetic solutions for this target molecule, leveraging our technical expertise to support industrial formulation development and pharmaceutical R&D.
Through our established peptide synthesis platform, we achieve efficient coupling of the pentamer sequence via optimized Solid-Phase Peptide Synthesis (SPPS). We execute precise head-to-tail backbone amide cyclization without disulfide bonds, strictly controlling impurity profiles during manufacturing. This ensures the final c(RGDyK) material meets exact purity specifications (routinely ≥98% via HPLC). This rigorous process control guarantees the batch-to-batch reproducibility required for both early-stage research and late-stage commercial formulation.
A key feature of c(RGDyK) is the availability of two independent attachment handles: the D-tyrosine phenol and the lysine side-chain amine. Leveraging this, we offer extensive peptide modification services. Researchers can request direct radioiodination at the tyrosine site for PET/SPECT tracer development, or conjugation at the lysine ε-amine with chelators, polymers, and fluorescent dyes. These structural adjustments enable researchers to precisely tune the molecule for dual-modality probes and advanced targeted delivery systems.
Scaling a cyclic peptide from benchtop research to commercial application demands stable manufacturing protocols. We facilitate efficient large-scale peptide synthesis for c(RGDyK), managing the transition from milligram screening batches to kilogram-scale production. Our large-scale infrastructure ensures a continuous, reliable supply chain for global pharmaceutical developers, supported by complete analytical documentation including COA, MS, and HPLC data for every delivered batch.
We function as a technical extension of our clients' teams, providing one-stop peptide formulation support. Our engineers assist clients in stability testing, degradation profiling, and identifying optimal handling conditions for c(RGDyK) in various matrices, taking into account the oxidation potential of the tyrosine phenol and the stability of backbone amides. By delivering precise analytical data alongside high-purity synthetic capacity, we enable R&D teams to execute complex targeted imaging and photodynamic therapy projects efficiently and confidently.
